CURIS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
CURIS, INC. (CRIS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period of 9.30 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod · last filed 2026-08-14
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-06-30 was -92.30K shares, a 230.49% decline year-over-year.
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2026-03-31 was 101.60K shares, a 97.71% increase year-over-year.
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-12-31 was 25.51K shares.
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for the quarter ending 2025-09-30 was 56.70K shares, a 38.00% decline year-over-year.
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2025 was 204.34K shares, a 2.73% increase from fiscal 2024.
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2024 was 198.90K shares, a 56.84% increase from fiscal 2023.
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2023 was 126.81K shares, a 95.69% decline from fiscal 2022.
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period for fiscal 2022 was 2.95M shares, a 1292.89% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | -92.30K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | 9.30K shares 10-Q · filed 2026-08-14 | 34.81K shares derived: sum of 3 quarters · filed 2026-08-14 | 91.51K shares derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | 101.60K shares 10-Q · filed 2026-05-13 | 127.11K shares derived: sum of 2 quarters · filed 2026-05-13 | 183.81K shares derived: sum of 3 quarters · filed 2026-05-13 | 254.55K shares derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | 25.51K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | 82.22K shares derived: sum of 2 quarters · filed 2026-03-24 | 152.95K shares derived: sum of 3 quarters · filed 2026-03-24 | 204.34K shares 10-K · filed 2026-03-24 |
| 2025-09-30 | 56.70K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 127.44K shares derived: sum of 2 quarters · filed 2025-11-06 | 178.82K shares 10-Q · filed 2025-11-06 | 178.82K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 70.73K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 122.12K shares 10-Q · filed 2025-08-05 | 122.12K shares derived: sum of 3 quarters · filed 2025-08-05 | 213.58K shares derived: sum of 4 quarters · filed 2025-08-05 |
| 2025-03-31 | 51.39K shares 10-Q · filed 2025-05-06 | 51.39K shares derived: sum of 2 quarters · filed 2025-05-06 | 142.85K shares derived: sum of 3 quarters · filed 2025-05-06 | 238.03K shares derived: sum of 4 quarters · filed 2025-05-06 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | 91.46K shares derived: sum of 2 quarters · filed 2025-03-31 | 186.64K shares derived: sum of 3 quarters · filed 2025-03-31 | 198.90K shares 10-K · filed 2025-03-31 |
| 2024-09-30 | 91.46K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 186.64K shares derived: sum of 2 quarters · filed 2024-11-14 | 198.90K shares 10-Q · filed 2024-11-14 | |
| 2024-06-30 | 95.17K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | 107.44K shares 10-Q · filed 2024-08-01 | ||
| 2024-03-31 | 12.26K shares 10-Q · filed 2024-05-07 | |||
| 2023-12-31 | 126.81K shares 10-K · filed 2024-02-08 | |||
| 2022-12-31 | 2.95M shares 10-K · filed 2023-03-13 | |||
| 2021-12-31 | 211.45K shares 10-K · filed 2022-02-24 | |||
| 2020-12-31 | 467.05K shares 10-K · filed 2021-03-16 | |||
| 2019-12-31 | 1.59M shares 10-K · filed 2020-03-19 | |||
| 2018-12-31 | 1.57M shares 10-K · filed 2019-03-26 | |||
| 2017-12-31 | 3.05M shares 10-K · filed 2018-03-08 | |||
| 2016-12-31 | 3.05M shares 10-K · filed 2017-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |